(DGX) Quest Diagnostics - Ratings and Ratios

Quest Diagnostics Incorporated (NYSE:DGX) stands as a leading provider of diagnostic testing and healthcare services, operating both domestically and internationally. The company specializes in delivering comprehensive diagnostic information services, encompassing routine, non-routine, and advanced clinical testing, along with anatomic pathology services. Through its diverse portfolio of brands, including Quest Diagnostics, AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, it serves a broad client base that includes physicians, hospitals, patients, health plans, government agencies, employers, pharmaceutical companies, and insurers. Its extensive network spans laboratories, patient service centers, and mobile healthcare professionals, ensuring wide-reaching access to essential services. Additionally, Quest Diagnostics offers risk assessment services for the life insurance sector and provides IT solutions tailored for healthcare organizations and clinicians. Established in 1967, the company is headquartered in Secaucus, New Jersey, and is a cornerstone in the health care services industry.

Quest Diagnostics Incorporated (NYSE:DGX) is poised for a period of moderate growth and stabilization over the next three months. Technically, the stock is trading slightly below its 20-day and 50-day moving averages, with a last price of $161.86 and an ATR of $4.75, indicating manageable volatility. The 200-day moving average of $155.58 suggests underlying strength. From a fundamental perspective, the companys market cap of $18.1 billion, P/E of 21.33, and forward P/E of 16.86 signal a reasonable valuation with potential for future earnings growth. The price-to-book ratio of 2.68 and return on equity of 12.85 further highlight its financial health and profitability. Over the next quarter, DGX is expected to trade within a range of $155 to $170, supported by its strong fundamentals and stable operational performance.